Fibraxis

Fibraxis is at the forefront of asthma treatment innovation, focusing on the commercialization of a novel inhalable medication designed to halt and reverse structural lung damage in asthma patients. Originating from Dr. Jill's laboratory at Aston University, Birmingham, this pioneering spin-out company leverages extensive research in biochemistry and biomedical science to uncover new therapeutic pathways. The company's drug candidate targets fibrosis by inhibiting chemotaxis, offering a transformative approach to asthma care. Fibraxis aims to provide patients with improved disease control and quality of life, marking a significant advancement in asthma management. The business model centers on translating scientific discoveries into market-ready solutions, with a commitment to delivering groundbreaking treatments to those in need. Fibraxis engages with both investors and patients, inviting collaboration and feedback to enhance its offerings. The company operates within the pharmaceutical and healthcare markets, serving asthma sufferers and stakeholders interested in cutting-edge medical therapies. Keywords: asthma, inhalable medication, fibrosis, chemotaxis, lung damage, biomedical research, commercialization, therapeutic target, patient care, pharmaceutical.